News

Fri, 25/05/2018
SFB/CRC-TR 128 retreat in Munich
Munich. The CRC-TR 128 “Multiple Sclerosis” corsially invites all its members – principal investigators as well as associated scientists and young investigators – to meet for a general scientific update, discussion and exchange at this year’s retreat. In addition to the PI meeting there will be a one-day conference especially for young investigators. When?: Thursday […]...more
Tue, 10/04/2018
Lecture: Environmental influence on the immune system
Mainz. The Research Center for Immunotherapy (FZI) and CRC 1292 are happy to welcome SFB 128 PI Prof. Karin Loser, MD, as a guest lecturer at their immunological seminar. Prof. Loser will talk about “Control of Immune responses by the environment”. When?: Thursday, April 26, 5:00 PM Where? University Medical Center Mainz, building 708, seminar […]...more
Fri, 16/03/2018
Lecture on Cell Interactions at the Blood-Brain-barrier
Muenster. The DFG-funded Comprehensive Research Centre “Breaking Barriers” cordially invites everyone interested in neuroimmunology to its upcoming Jour-Fixe Meeting where Luisa Klotz and Heinz Wiendl – both acting as PIs in the DFG-funded CRC “Multiple Sclerosis” (128) as well as “Breaking Barriers” (1009) – will hold a lecture on “Immune Cell Interactions with Endothelial Cells […]...more


Thu, 09/11/2017 | Elisabeth Schuh received SEED funding

Munich. SFB 128 researcher Elisabeth Schuh, MD, has been honoured by a young scientist’s studentship within the KKNMS SEED program. In her project „The role of the NLRP3 inflammasome in multiple sclerosis and experimental autoimmune encephalomyelitis“, Dr. Schuh analyses the influence of the NLRP3in MS. NLRP is a cytosolic protein complex in monocytes, macrophages and neutrophil granolucytes that regulated the production of inflammatory cytokines of the interleukin-1 family. In her project, Dr. Schuh wants to identify the population of myeloid cells involved in MS pathogenesis, with the aim of finding new pathways for therapeutic intervention that prevent autoimmune tissue damage.
The SEED program addresses scientists younger than 32 years who have not yet completed their medical training. The maximum funding is 32.000 € or 75 percent of the project’s budget. The remaining 25% have to be paid by the stipend’s employee.